Abstract:Meningioma is the most common primary brain tumor and many studies have evaluated numerous biomarkers for their prognostic value, often with inconsistent results. Currently, no reliable biomarkers are available to predict the survival, recurrence, and progression of meningioma patients in clinical practice. This study aims to evaluate the prognostic value of immunohistochemistry-based (IHC) biomarkers of meningioma patients. A systematic literature search was conducted up to November 2023 on PubMed, CENTRAL, CINAHL Plus, and Scopus databases. Two authors independently reviewed the identified relevant studies, extracted data, and assessed the risk of bias of the studies included. Meta-analyses were performed with the hazard ratio (HR) and 95% confidence interval (CI) of overall survival (OS), recurrence-free survival (RFS), and progression-free survival (PFS). The risk of bias in the included studies was evaluated using the Quality in Prognosis Studies (QUIPS) tool. A total of 100 studies with 16,745 patients were included in this review. As the promising markers to predict OS of meningioma patients, Ki-67/MIB-1 (HR = 1.03, 95%CI 1.02 to 1.05) was identified to associate with poor prognosis of the patients. Overexpression of cyclin A (HR = 4.91, 95%CI 1.38 to 17.44), topoisomerase II α (TOP2A) (HR = 4.90, 95%CI 2.96 to 8.12), p53 (HR = 2.40, 95%CI 1.73 to 3.34), vascular endothelial growth factor (VEGF) (HR = 1.61, 95%CI 1.36 to 1.90), and Ki-67 (HR = 1.33, 95%CI 1.21 to 1.46), were identified also as unfavorable prognostic biomarkers for poor RFS of meningioma patients. Conversely, positive progesterone receptor (PR) and p21 staining were associated with longer RFS and are considered biomarkers of favorable prognosis of meningioma patients (HR = 0.60, 95% CI 0.41 to 0.88 and HR = 1.89, 95%CI 1.11 to 3.20). Additionally, high expression of Ki-67 was identified as a prognosis biomarker for poor PFS of meningioma patients (HR = 1.02, 95%CI 1.00 to 1.04). Although only in single studies, KPNA2, CDK6, Cox-2, MCM7 and PCNA are proposed as additional markers with high expression that are related with poor prognosis of meningioma patients. In conclusion, the results of the meta-analysis demonstrated that PR, cyclin A, TOP2A, p21, p53, VEGF and Ki-67 are either positively or negatively associated with survival of meningioma patients and might be useful biomarkers to assess the prognosis.

Decreased expression of LASS2 is associated with worse prognosis in meningiomas

LAMP1 Expression is Associated with Malignant Behaviours and Predicts Unfavourable Prognosis in Laryngeal Squamous Cell Carcinoma.

Association Between Laminin Γ1 Expression and Meningioma Grade, Recurrence, and Progression-Free Survival

Enhancer of zeste homolog 2 is a negative prognostic biomarker and correlated with immune infiltrates in meningioma

Overexpression of RLIP76 Required for Proliferation in Meningioma is Associated with Recurrence.

LASS2 impairs proliferation of glioma stem cells and migration and invasion of glioma cells mainly via inhibition of EMT and apoptosis promotion

Prognostic Value of Ki-67/MIB-1 Expression in Meningioma Patients: A Meta-analysis

High expression of apoptosis-related LMNB2 predicts an unfavorable outcome: A potential prognostic biomarker for liposarcoma

Biom-16. A Targeted Gene Expression Biomarker Predicts Low Grade Meningioma Recurrence And Overall Survival

Prognostic Value of Ki-67/MIB-1 Expression in Meningioma Patients: A Meta-Analysis.

LSM2 is Associated with a Poor Prognosis and Promotes Cell Proliferation, Migration, and Invasion in Skin Cutaneous Melanoma

Expression and Significance of LUC7L3 and Ki-67 in Meningiomas

Downregulation of LUZP2 is Correlated with Poor Prognosis of Low-Grade Glioma

Biomarkers for prognosis of meningioma patients: A systematic review and meta-analysis

The level of periostin in meningiomas and its clinical significance

The Expression Of Disabled-2 Is Common Reduced In Meningiomas

Tumor-infiltrating lymphocytes-derived MLL2 independently predicts disease-free survival for patients with early-stage oral squamous cell carcinoma.

A targeted gene expression biomarker predicts clinic low-risk meningioma recurrence

Long Noncoding RNA CASC2 Predicts the Prognosis of Glioma Patients and Functions As a Suppressor for Gliomas by Suppressing Wnt/β-catenin Signaling Pathway

PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor

Increased Expression of the 58-Kd Microspherule Protein (MSP58) is Correlated with Poor Prognosis in Glioma Patients